ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,518.38
0.49%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Clearmind Medicine Inc (CMND)

  7. Clearmind Medicine Inc (CMND) News

Clearmind Medicine (CMND)

Clearmind Medicine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CMND
DateTimeSourceHeadlineSymbolCompany
13/06/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
13/06/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
11/06/202412:44GlobeNewswire Inc.Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based DrinkNASDAQ:CMNDClearmind Medicine Inc
10/05/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
10/05/202413:24GlobeNewswire Inc.Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage ProductNASDAQ:CMNDClearmind Medicine Inc
07/05/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
07/05/202412:46GlobeNewswire Inc.Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentNASDAQ:CMNDClearmind Medicine Inc
30/04/202421:15GlobeNewswire Inc.Clearmind Applies to Cease Being a Reporting Issuer in CanadaNASDAQ:CMNDClearmind Medicine Inc
17/04/202412:49GlobeNewswire Inc.Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersNASDAQ:CMNDClearmind Medicine Inc
10/04/202412:17GlobeNewswire Inc.Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersNASDAQ:CMNDClearmind Medicine Inc
09/04/202413:07GlobeNewswire Inc.Clearmind Medicine CEO Issues Letter to ShareholdersNASDAQ:CMNDClearmind Medicine Inc
19/03/202411:55GlobeNewswire Inc.Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in ChinaNASDAQ:CMNDClearmind Medicine Inc
13/03/202412:14GlobeNewswire Inc.Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialNASDAQ:CMNDClearmind Medicine Inc
13/03/202411:30GlobeNewswire Inc.Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeNASDAQ:CMNDClearmind Medicine Inc
27/02/202412:58GlobeNewswire Inc.Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine CompoundsNASDAQ:CMNDClearmind Medicine Inc
27/02/202412:58GlobeNewswire Inc.SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine CompoundsNASDAQ:CMNDClearmind Medicine Inc
23/02/202412:06GlobeNewswire Inc.Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderNASDAQ:CMNDClearmind Medicine Inc
20/02/202412:14GlobeNewswire Inc.Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based CompoundsNASDAQ:CMNDClearmind Medicine Inc
20/02/202412:14GlobeNewswire Inc.SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based CompoundsNASDAQ:CMNDClearmind Medicine Inc
05/02/202412:51GlobeNewswire Inc.Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in ChinaNASDAQ:CMNDClearmind Medicine Inc
01/02/202413:15GlobeNewswire Inc.Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research CenterNASDAQ:CMNDClearmind Medicine Inc
16/01/202416:19GlobeNewswire Inc.Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private PlacementNASDAQ:CMNDClearmind Medicine Inc
11/01/202414:28GlobeNewswire Inc.Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private PlacementNASDAQ:CMNDClearmind Medicine Inc
10/01/202412:18GlobeNewswire Inc.Clearmind Medicine Completed Type A Meeting with the FDANASDAQ:CMNDClearmind Medicine Inc
04/01/202412:18GlobeNewswire Inc.Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based TreatmentsNASDAQ:CMNDClearmind Medicine Inc
04/01/202412:18GlobeNewswire Inc.SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based TreatmentsNASDAQ:CMNDClearmind Medicine Inc
14/12/202313:26GlobeNewswire Inc.Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing StandardsNASDAQ:CMNDClearmind Medicine Inc
05/12/202313:47GlobeNewswire Inc.Clearmind Medicine Achieved Positive Results in Cocaine Addiction TreatmentNASDAQ:CMNDClearmind Medicine Inc
01/12/202313:14GlobeNewswire Inc.Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical TrialNASDAQ:CMNDClearmind Medicine Inc
28/11/202313:25GlobeNewswire Inc.Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based TreatmentNASDAQ:CMNDClearmind Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:CMND

Your Recent History

BIT
UC92T4
Unicredit Bank
COIN
ARN1UST
Arrant 1
USOTC
AHLJS
RSE Archive (GM)
TSXV
TSC
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved